NASDAQ : GPCR
Structure Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 21.94 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.56B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.56B |
| Enterprise Value | 223.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 71.31M |
| Shares Change (YoY) | +16.35% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 2.44% |
| Owned by Institutions (%) | 82.28% |
| Float | 55.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 31.19 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 20.75 |
| Quick Ratio | 20.31 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -20.21% |
| Return on Assets (ROA) | -14.95% |
| Return on Invested Capital (ROIC) | -15.65% |
| Return on Capital Employed (ROCE) | -19.72% |
| Weighted Average Cost of Capital (WACC) | -3.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$764,537 |
| Employee Count | 281 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 702,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.37 |
| 52-Week Price Change | -26.04% |
| 50-Day Moving Average | 33.44 |
| 200-Day Moving Average | 49.06 |
| Relative Strength Index (RSI) | 26.52 |
| Average Volume (20 Days) | 1,134,225 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.15M |
| Short Previous Month | 7.54M |
| Short % of Shares Out | 13.72% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -268.06M |
| Pretax Income | -214.13M |
| Net Income | -214.84M |
| EBITDA | -265.79M |
| EBIT | -268.06M |
| Earnings Per Share (EPS) | -$3.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.34B |
| Total Debt | 6.23M |
| Net Cash | 1.34B |
| Net Cash Per Share | $18.74 |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 19.02 |
| Working Capital | 1.31B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -220.29M |
| Capital Expenditures | -4.21M |
| Depreciation & Amortization | 2.27M |
| Net Borrowing | n/a |
| Free Cash Flow | -224.50M |
| FCF Per Share | -$3.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.35% |
| Shareholder Yield | n/a |
| Earnings Yield | -14.72% |
| FCF Yield | -14.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $107.29 |
| Price Target Difference | 390.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |